NASDAQ:SBTX Silverback Therapeutics (SBTX) Stock Price, News & Analysis → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Free SBTX Stock Alerts $8.09 -0.17 (-2.06%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$7.66▼$8.1950-Day Range$7.10▼$10.2252-Week Range$2.80▼$8.97Volume534,599 shsAverage Volume337,931 shsMarket Capitalization$291.71 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsInsider TradesOwnershipSEC FilingsSocial MediaStock AnalysisChartCompetitorsFinancialsInsider TradesOwnershipSEC FilingsSocial Media Get Silverback Therapeutics alerts: Email Address Ad Stansberry ResearchWorld’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do. About Silverback Therapeutics Stock (NASDAQ:SBTX)Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Read More SBTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SBTX Stock News HeadlinesApril 25, 2024 | americanbankingnews.comSilverback Therapeutics (NASDAQ:SBTX) Trading Down 2.8%May 11, 2023 | uk.investing.comARS Pharmaceuticals Inc (SPRY)April 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.January 24, 2023 | seekingalpha.comSPRY ARS Pharmaceuticals, Inc.November 22, 2022 | 247wallst.comARS Pharma CEO Richard Lowenthal Holds 8% Silverback Stake After MergerNovember 18, 2022 | nasdaq.comDr. Sarina Tanimoto Discloses Position in SBTX / Silverback TherapeuticsNovember 10, 2022 | finance.yahoo.comARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including AnaphylaxisNovember 8, 2022 | finance.yahoo.comARS Pharmaceuticals Closes Merger with Silverback TherapeuticsApril 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.October 28, 2022 | markets.businessinsider.comSilverback : FDA Accepts ARS Pharm's NDA For Neffy For Treatment Of Allergic ReactionsOctober 21, 2022 | finance.yahoo.comSilverback Therapeutics, Inc. announces the FDA’s acceptance of ARS Pharmaceuticals’ NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including AnaphylaxisSeptember 17, 2022 | markets.businessinsider.comINVESTIGATION ALERT: Halper Sadeh LLC Investigates CVET, SBTX, IRBTSeptember 15, 2022 | seekingalpha.comSBTX Silverback Therapeutics, Inc.September 6, 2022 | markets.businessinsider.comSHAREHOLDER NOTICE: Halper Sadeh LLP Investigates FTAI, SBTX, CVET, GBTAugust 23, 2022 | markets.businessinsider.comSHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates HNGR, SBTX, IEA, ZYAugust 17, 2022 | apnews.comSHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates VIVO, HNGR, SBTXAugust 11, 2022 | apnews.comSHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates IEA, BBQ, SBTXJuly 30, 2022 | morningstar.comSHAREHOLDER ALERT: Weiss Law Reminds SBTX, LJPC, CNVY, and DRE Shareholders About Its Ongoing InvestigationsJuly 28, 2022 | apnews.comINVESTIGATION ALERT: Halper Sadeh LLP Investigates HNGR, SBTX, IEA, ZYJuly 27, 2022 | benzinga.comShareholder Alert - The M&A Class Action Firm Announces the Investigation of Silverback Therapeutics, Inc. - SBTXJuly 26, 2022 | apnews.comLifshitz Law PLLC Announces Investigation of IEA, ZY, SBTX, and HNGRJuly 26, 2022 | finance.yahoo.comSilverback Therapeutics plans merger with San Diego biotechJuly 25, 2022 | apnews.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates HNGR, SBTX, UJuly 22, 2022 | benzinga.comSILVERBACK THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of SBTX and Encourages Investors to Contact the FirmJuly 22, 2022 | prnewswire.comSHAREHOLDER ALERT: Weiss Law Investigates Silverback Therapeutics, Inc.July 22, 2022 | apnews.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates HNGR, ONEM, SBTX, ZENJuly 22, 2022 | finance.yahoo.comOnce A Cancer Company, Silverback Merges With Small Biotech Working On Allergy TreatmentSee More Headlines Receive SBTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Silverback Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today4/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SBTX CUSIPN/A CIK1671858 Webwww.silverbacktx.com Phone206 456 2900FaxN/AEmployees83Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-89,480,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-29.62% Return on Assets-28.20% Debt Debt-to-Equity RatioN/A Current Ratio67.87 Quick Ratio67.87 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.41 per share Price / Book1.09Miscellaneous Outstanding Shares36,058,000Free Float23,654,000Market Cap$291.71 million OptionableNot Optionable Beta0.60 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Peter A. Thompson FACP (Age 62)M.D., Co-Founder & Chairman of Directors Comp: $5.12kMr. Jeffrey C. Pepe J.D.Ph.D., Interim CEO, Gen. Counsel & Corp. Sec.Mr. Russ Hawkinson (Age 63)Sr. VP of Fin., Interim CFO, Principal Financial Officer & Principal Accounting Officer Mr. Miguel Arcinas M.B.A.VP of Corp. Devel. & Investor RelationsJen MoreDirector of HRMs. Sue HamkeSr. VP of Clinical OperationsMr. Dario Gobunquin CPASr. Director of Accounting & ControllerMore ExecutivesKey CompetitorsVentyx BiosciencesNASDAQ:VTYXXOMANASDAQ:XOMATerns PharmaceuticalsNASDAQ:TERNAquestive TherapeuticsNASDAQ:AQSTAtea PharmaceuticalsNASDAQ:AVIRView All Competitors SBTX Stock Analysis - Frequently Asked Questions How have SBTX shares performed in 2024? Silverback Therapeutics' stock was trading at $5.48 at the beginning of the year. Since then, SBTX shares have increased by 47.6% and is now trading at $8.09. View the best growth stocks for 2024 here. How were Silverback Therapeutics' earnings last quarter? Silverback Therapeutics, Inc. (NASDAQ:SBTX) issued its earnings results on Wednesday, November, 10th. The company reported ($0.65) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.65). When did Silverback Therapeutics IPO? Silverback Therapeutics (SBTX) raised $126 million in an IPO on Friday, December 4th 2020. The company issued 7,000,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs, SVB Leerink and Stifel acted as the underwriters for the IPO and H.C. Wainwright was co-manager. How do I buy shares of Silverback Therapeutics? Shares of SBTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SBTX) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsYour Money is Not SafeAmerican AlternativeJim Cramer’s “The Biggest Drug Ever”Behind the MarketsThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silverback Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
